About Sigilon
Sigilon is a Healthcare company based in Cambridge (United States) founded in 2015 by Omid Veiseh, and was acquired by Lilly in June 2023. Therapeutics for chronic diseases are developed via cell engineering platforms. Sigilon has raised $103.8 million across 3 funding rounds from investors including Lilly, BlackRock and Flagship Pioneering. The company has 66 employees. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its competitors include Neurocrine, Crinetics and MBX Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Sigilon was founded in 2015 in Cambridge, United States, within the biotechnology sector. Therapeutics targeting chronic diseases are created using cell engineering and proprietary biocompatible materials. The Shielded Living Therapeutics (SLTx) platform is employed to address various conditions. A pipeline is maintained for rare blood disorders, lysosomal diseases, and endocrine diseases, with operations focused on therapeutic development.
- Headquarters Cambridge, United States
- Employees 66
- Founders Omid Veiseh
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website sigilon.com
- Social LinkedIn X Facebook
- Acquired by Lilly (Jun 2023)
Funding Insights of Sigilon
Sigilon has successfully raised a total of $103.8M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $80.3 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $103.8M
- Total Rounds 3
- Last Round Series B — $80.3M
- First Round $23.5M
(Jun 2017)
- Investors Count 5
All 3 funding rounds of Sigilon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $80.3M | Series B | – | CPP Investments | |
| Apr 2018 | Series A | – | – | ||
| Jun 2017 | $23.5M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Sigilon
Sigilon has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, BlackRock and Flagship Pioneering.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Support is provided for longevity breakthrough initiatives by Longevity Vision Holding. | lvf.vc | New York, USA | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Pension fund assets are managed for sustainable long-term growth. | 1997 | cppinvestments.com | Toronto, Canada | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 1988 | blackrock.com | New York, United States |
Investor details for Sigilon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sigilon
28 people are tracked at Sigilon (11 in leadership, 7 in board & advisors, 10 in team); the tracked headcount is 66.
| Name | Role | Group |
|---|---|---|
Omid Veiseh | Co-Founder | Leadership |
Eric Shaff | Corporate Director | Leadership |
Olivia G. Kelly | VP, Head, Islet Cell Therapy Research | Leadership |
Sarah Yuan | Chief Technical Operations Officer | Leadership |
Rogerio Vivaldi | President & CEO | Leadership |
Philip Ashton-Rickardt | Chief Scientific Officer | Leadership |
Jiang Wu | VP & Head, Bioanalytical & CMC Analytical Development | Leadership |
Jamie Murphy | VP, Finance & Controller | Leadership |
Joseph Tumang | VP & Head, Immune Mediated Diseases | Leadership |
Michael Owings | Head Of Quality | Leadership |
Jamie M. | VP Of Finance & Controller | Leadership |
Ulrik B. Nielsen | Advisor | Board & advisors |
Robert Langer | Advisor | Board & advisors |
Arturo Vegas | Founder | Board & advisors |
Michael Rosenblatt | Advisor | Board & advisors |
Constance Cepko | Advisor | Board & advisors |
Daniel G. Anderson | Founder & Scientific Advisor | Board & advisors |
José Oberholzer | Founder | Board & advisors |
Monica Keating | Prinical Associate Scientist | Team |
Junianna Borgia | ICT Research Assistant | Team |
8 more people are available in the full profile.
Complete people profiles for Sigilon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sigilon
5 dated milestones of Sigilon across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Sigilon is founded.
- Funding First funding round of $23.5M.
- Funding Latest funding round, Series B, of $80.3M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Lilly.
Competitors of Sigilon
Sigilon has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, Crinetics and MBX Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| mbxbio.com | 2018 | Carmel, United States | $215.6M | 11 | Drugs for rare endocrine diseases are developed and advanced. |
Detailed competitors of Sigilon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Sigilon (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sigilon
Complete news archive for Sigilon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sigilon
Sigilon was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Sigilon is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Sigilon is a funded company, having raised a total of $103.8M across 3 funding rounds to date. The company's 1st funding round was a Series A of $23.5M, raised on Jun 2017.
Sigilon has 66 employees.
Sigilon was founded in 2015 in Cambridge, United States, within the biotechnology sector. Therapeutics targeting chronic diseases are created using cell engineering and proprietary biocompatible materials. The Shielded Living Therapeutics (SLTx) platform is employed to address various conditions. A pipeline is maintained for rare blood disorders, lysosomal diseases, and endocrine diseases, with operations focused on therapeutic development.
Sigilon's top competitors include Crinetics, Neurocrine and MBX Biosciences.
Sigilon has 5 investors. Key investors include Lilly, BlackRock, Flagship Pioneering, CPP Investments, and Longevity Vision Holding.
Yes. Sigilon was acquired by Lilly in June 2023.